Advancing TB Vaccine Innovation: Lung Immunity and mRNA Technology Take Center Stage in Africa’s Fight Against Tuberculosis
During African Vaccination Week 2026, the urgent need for more effective tuberculosis (TB) vaccines has come into sharp focus, with researchers exploring innovative strategies to combat one of the world’s deadliest infectious diseases. Scientists at the University of the Witwatersrand, led by Kristie Bloom, are pioneering next-generation approaches that target lung immunity using mRNA vaccine platforms. Their work focuses on stimulating tissue-resident memory T-cells—specialised immune cells that remain in the lungs and act as early responders to infection. Unlike traditional vaccines such as Bacillus Calmette–Guérin vaccine, which offer inconsistent protection against pulmonary TB in adults, mRNA-based strategies aim to generate stronger cellular immune responses. With tuberculosis continuing to place a heavy burden on Africa, particularly in South Africa, this research highlights the potential for locally driven vaccine innovation. Supported by global collaborations, the initiative represents a significant step toward developing faster, more effective, and regionally relevant solutions to control TB transmission and improve global health outcomes.
